Navigation Links
Diabetes drug class linked to vision-threatening complication
Date:4/2/2009

Philadelphia, PA, 2 April 2009 Treatment with the glitazone class of diabetes drugs leads to a "modest" increase in the risk of diabetic macular edema (DME)a common complication that can lead to vision loss, reports a study in the April issue of the American Journal of Ophthalmology (http://www.elsevier.com/locate/ajo), published by Elsevier.

Using a database of about 170,000 patients with diabetes, Drs. Donald S. Fong and Richard Contreras of Southern California Permanente Medical Group analyzed the link between glitazones and the development of DME. Diabetic macular edema is a common diabetes complication, with swelling and fluid build-up in the retina leading to progressive visual loss.

The researchers identified 996 patients who were diagnosed with DME during 2006. Overall, patients who took glitazones were 2.6 times more likely to develop DME than patients not taking these drugs. Even after further adjustment for other factors, DME risk remained 60 percent higher for glitazone users.

Previous studies have linked glitazones to problems related to fluid retention and edema (swelling), including heart failure. Fluid retention from heart failure or other diseases can worsen DME. Most of the glitazone users in the study were taking pioglitazone (Actos). Other studies have linked rosiglitazone (Avandia)the only other approved glitazone drugto a possible increase in the risk of myocardial infarction.

Although the study is not the first to suggest a link, it provides confirmation in a very large sample of diabetic patients that glitazones are "modestly associated" with DME. Drs. Fong and Contreras concluded, "When treating patients with DME, ophthalmologists should consider the role of the glitazone class of drugs."

"Ocular complications are an overlooked safety issue of systemic drugs," commented Dr. Thomas J. Liesegang, Editor-in-Chief of AJO, "Safety is as important as the efficacy of a drug. However, long term safety is not currently monitored because the approval process is based on smaller, shorter term clinical trials. Safety necessarily requires monitoring of treatment in larger groups of people over longer periods of time. This monitoring is often neglected and should be required of all therapies."


'/>"/>

Contact: Maureen Hunter
m.hunter@elsevier.com
215-239-3671
Elsevier
Source:Eurekalert

Related medicine news :

1. Lack of Awareness of Eye Health Risk Associated with Diabetes Poses Blinding Threat to Millions
2. Anthem Blue Cross and Blue Shield, Eli Lilly and Company Establish Coalition to Help Improve the Health of Indiana Residents with Diabetes
3. Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive
4. Survey Reveals Honolulu Residents Perceive Financial Challenges as Main Barrier in Properly Managing Their Type 2 Diabetes
5. American Diabetes Association Alert(R) Day Video - Do You Have Diabetes?
6. Many Americans Fear Being Diagnosed With Diabetes
7. Supermodel Izabel Goulart Partners With Diabetes Research Institute Foundation as International Ambassador
8. City Councilors Nancy White, RN, Charles Jones, and Ed DeFore Launch Medicare Diabetes Screening Project in Macon
9. Home Care Delivered, Inc. Recognizes 21st Annual American Diabetes Alert Day
10. South Asians with diabetes more likely to lose their eyesight earlier than white Europeans
11. Control or Prevent Diabetes Through Healthier Habits, Pennsylvania Health Secretary Urges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief ... advancements to physician colleagues, skilled nursing facility medical directors and other clinicians at ... of Wound Care." , "At many of these conferences we get to educate ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017   Divoti USA ... Jewelry up to the standard of the latest FDA requirements, which ... 2017). Anyone in need of Medical ID jewelry such ... Alert Jewelry are engraved in terms of the new ... Divoti offers ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
Breaking Medicine Technology: